Geron falls after discontinuing late-stage cancer trial

** Shares of Geron GERN.O fall 6.1% to $1.08 premarket

** Co to discontinue its late-stage trial testing its treatment for patients with a form of rare blood cancer

** Co was testing the drug branded as Rytelo as a treatment for myelofibrosis, a rare type of blood cancer

** Co made the decision following an independent data monitoring committee's recommendation that the trial was unlikely to achieve its main goal of overall survival

** A detailed analysis of the data will be conducted, and study findings will be shared at a future date, co says

** Up to last close, stock has fallen 12.9% YTD